Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Immuron Ltd Declaration of Voting Results & Voting Rights Announcements 2013

Nov 28, 2013

35121_rns_2013-11-28_f23c3ac8-8b48-4926-bb6a-55b305ee46da.pdf

Declaration of Voting Results & Voting Rights Announcements

Open in viewer

Opens in your device viewer

==> picture [192 x 41] intentionally omitted <==

Level 1, 18 Kavanagh Street Southbank, Vic 3006 Tel: +61 (0)3 8648 4530 Fax: +61 (0)3 9686 9460 www.immuron.com ABN: 80 063 114 045

Immuron Limited

(ASX: IMC)

RESULTS OF ANNUAL GENERAL MEETING

Friday 29[th] November 2013

The Company wishes to advise that all resolutions were carried on show of hands.

In accordance with Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, the following information is provided in relation to the resolutions considered by Members of the Company at the Annual General Meeting held today.

Resolution Resolution For Against Abstain Proxy'sDiscretion* Total ValidProxiesReceived
1 Adoption of Remuneration Report 238,174,139 2,945,786 64,492,498 169,534,561 475,146,984
2 Election of Daniel Pollock as a Director 189,334,855 694,481 65,583,087 219,534,561 475,146,984
3 Election of Stephen Anastasiou as a Director 195,752,848 695,481 109,164,094 169,534,561 475,146,984
4 Approve the issue of 8,750,000 Shares to Grandlodge Pty Ltd 195,467,295 60,145,128 168,326,929 51,207,632 475,146,984
5 Approve the issue of 2,604,167 Shares and 20,000,000 Options to Roger Aston 195,467,295 981,034 59,164,094 219,534,561 475,146,984
6 Approve the issue of 1,875,000 Shares and 10,000,000 Options to Daniel Pollock 189,048,302 60,145,128 6,418,993 219,534,561 475,146,984
7 Approve the issue of 10,000,000 Options to Stephen Anastasiou 195,467,295 60,145,128 50,000,000 169,534,561 475,146,984
8 Approve the issue of 5,000,000 Shares and 10,000,000 Options to The CFO Solution 252,131,389 981,034 2,500,000 219,534,561 475,146,984
9 Appointment of William Buck Audit (VIC) Pty Ltd as the Company's auditor 255,279,892 238,245 94,286 219,534,561 475,146,984
10 Approval of additional capacity to issue Shares under ASX Listing Rule 7.1A 188,932,387 66,680,036 - 219,534,561 475,146,984
  • The Chairman voted undirected proxies in his control in favour of all resolutions.

On behalf of the Board

==> picture [80 x 58] intentionally omitted <==

Phillip Hains Company Secretary

About Immuron Limited

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron is uniquely positioned with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre-clinical studies relatively quickly and increases the prospect that the clinical development of Immuron’s products will be expedited. Immuron’s current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver/NASH, and influenza. Immuron has a product in the market, Travelan, for preventing travellers’ diarrhoea.

Page 1 of 1